Karen Reckamp, MD
In just 1 year, the treatment paradigm of non–small cell lung cancer (NSCLC) shifted dramatically in varying patient populations, especially in those with molecular abnormalities—such as EGFR
translocations, and BRAF
mutations—high levels of PD-L1 expression, and even in those without any expression of PD-L1.
Reckamp, associate professor and medical director for clinical trial operations, City of Hope, highlighted some of the key advancements in the lung cancer landscape in an interview during the meeting, focusing specifically on positive phase III data, recent regulatory approvals, and what research the new year is likely to bring.
OncLive: Could you reflect on recent advancements in lung cancer?
: The landscape of lung cancer treatment has changed dramatically. Even in the past year, we have a multitude of drugs that have been approved and new genes that have been identified that are potential targets for new drugs and immunotherapy.
... to read the full story